Specific Biologics' mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body.
We are actively developing a platform technology consisting of a dual-cleaving nuclease that can be safely delivered to cells for the treatment of various genetic diseases. This technology is designed to better exploit the cell's naturally occurring DNA repair pathways through enhanced repair or predictable deletions.
We are actively developing a platform technology consisting of a dual-cleaving nuclease that can be safely delivered to cells for the treatment of various genetic diseases. This technology is designed to better exploit the cell's naturally occurring DNA repair pathways through enhanced repair or predictable deletions.
Location: Canada, Ontario, Toronto
Employees: 1-10
Founded date: 2017
Investors 3
| Date | Name | Website |
| 19.12.2021 | Lumira Ven... | lumiravent... |
| - | Canadian T... | ctaconnect... |
| - | Creative D... | creativede... |
Mentions in press and media 2
| Date | Title | Description |
| 16.10.2023 | Specific Biologics Receives Additional Investment | Specific Biologics, a Toronto, Canada-based early-stage biotechnology company, received an additional investment from Lumira Ventures and adMare BioInnovations. The amount of the deal was not disclosed. In conjunction with the investment, S... |
| 16.12.2021 | Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations | Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December 16, 2021] Speci... |